Bm-sev
Bm-sev has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Jun 18, 2026: “Dual-engineered small extracellular vesicles targeted delivery miR-126 for reducing age-related bone loss”.
1 paper studies it2 findingsUpdated
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: National Natural Science Foundation of China and 1 more
- Animals1
What did studies of bm-sev find?
2Studies of bm-sev measured 2 outcomes: age-related bone loss and type H vessels.
Age-related bone loss
downin rats1
1 study
Age-related bone loss
downin rats1
Bm-sev decreases age-related bone loss in rats (aged femurs).
Animalsaged femursbone-targeting engineered vesicles (Bm-sEV)femur
Type H vessels
upin rats1
1 study
Type H vessels
upin rats1
Bm-sev increases type H vessels in rats (aged femurs).
Animalsaged femursbone-targeting engineered vesicles (Bm-sEV)femur